![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the... Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Show more
Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, July 18, 2024 NEW YORK, July 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second...
Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024...
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit Meeting WALTHAM, Mass., June 10...
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global...
Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were clearedHighlighted as...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.74 | -9.18242082003 | 40.73 | 42.47 | 36.3 | 1286917 | 38.61799505 | CS |
4 | -1.74 | -4.49264136328 | 38.73 | 42.47 | 34.69 | 1324138 | 38.24466851 | CS |
12 | -9.61 | -20.6223175966 | 46.6 | 49.06 | 34.69 | 1462203 | 41.07826424 | CS |
26 | -26.82 | -42.0310296192 | 63.81 | 71.9 | 34.69 | 1396378 | 51.24858713 | CS |
52 | 2.77 | 8.09468147282 | 34.22 | 73.8 | 19.8301 | 2341363 | 44.8424878 | CS |
156 | -28.79 | -43.7671024628 | 65.78 | 94.75 | 19.8301 | 1782531 | 50.52942472 | CS |
260 | 7.92 | 27.2445820433 | 29.07 | 94.75 | 16.85 | 1403840 | 47.52019727 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions